ZERO Prostate Cancer Unveils 2026 Advocacy Summit to Benefit Veterans and Their Care

ZERO Prostate Cancer 2026 Advocacy Summit and Veterans Action Convening

In a groundbreaking initiative announced by ZERO Prostate Cancer, the 2026 ZERO Prostate Cancer Advocacy Summit is set to take place at the Hilton Washington, D.C. Capitol Hill. This significant event aims to mobilize advocates and stakeholders, focusing on making prostate cancer a national priority. The Summit starts on February 22, 2026, and features the distinguished Bold for Blue Award Ceremony, celebrating those who have made remarkable contributions to the prostate cancer community.

The event continues on February 23 with expert-led sessions designed to empower participants by providing vital tools for advocacy. Attendees will engage directly with lawmakers on Capitol Hill to advocate for crucial policies that will enhance access to screening and treatment for prostate cancer.

Pfizer’s Senior Director of Patient Advocacy, Lance Barbour, stated, "We are honored to support the ZERO Prostate Cancer Advocacy Summit, which unites patients, caregivers, clinicians, and advocates in Washington, D.C. to advance policies that improve access to screening, treatment, and research. At Pfizer, we believe progress happens through collaboration, and we are proud to stand with ZERO and the prostate cancer community."

Just weeks following the Summit, the 2026 Veterans' Action Convening will occur on March 24-25, 2026, in Arlington, Virginia. This gathering aims to enhance care, support, and outcomes for veterans facing prostate cancer, a demographic at heightened risk yet often hindered by barriers in accessing timely care. Veteran survivors, advocates, and healthcare professionals will collaborate to address these issues directly.

Paul Caseley, Veterans Program Manager at ZERO Prostate Cancer, emphasized the need for increased awareness and improved access to care for veterans. "Veterans have earned access to the highest standard of cancer care, yet too many face delays, gaps, or confusion when navigating prostate cancer screening and treatment. We aim to listen to veterans and transform shared knowledge into action that improves healthcare quality and accessibility."

During the two-day convening, participants will review findings from a national survey detailing veterans' experiences with prostate cancer, contributing to a coalition focused on advancing solutions. This coalition is essential in steering ZERO's initiatives for veterans moving forward.

Carmen White from Pfizer elaborated on the company’s commitment to eliminating disparities in cancer care: "Increasing awareness and ensuring equitable access to innovations like biomarker testing is critical. Every veteran, regardless of geographic or systemic barriers, should benefit from timely, personalized treatment."

The event is reinforced by sponsors such as AstraZeneca, which echoed the necessity for improved testing access and community awareness. Daniele Paone, VP of GYN and GU Cancers at AstraZeneca, noted, "To progress in the fight against prostate cancer, we must focus on better serving veterans and improving the overall patient experience."

As the leading advocate against prostate cancer, ZERO Prostate Cancer emphasizes breaking down the barriers that hinder timely and effective treatment for patients. Founded in 1996, the organization has dedicated over three decades to supporting those affected by prostate cancer, pushing for necessary funding and awareness while enhancing access to care.

In summary, the 2026 Advocacy Summit and Veterans Action Convening represent a pivotal moment for those involved in prostate cancer advocacy, uniting a community driven to improve the landscape of prostate cancer care for veterans and beyond. For more information and to join the advocacy journey, visit zerocancer.org/take-action/advocate.

About ZERO Prostate Cancer

ZERO Prostate Cancer is focused on improving the lives of individuals impacted by prostate cancer through advocacy, education, and support. Established to represent men and families affected by prostate cancer, ZERO aims for a future characterized by early detection and accessible care.

To learn more about their work, please visit ZERO Cancer's official website.